Gynoflor

Gynoflor is a prescription vaginal tablet that combines the estrogen estriol with the probiotic Lactobacillus acidophilus. Each tablet is formulated for local vaginal administration and is marketed in the European Union for the treatment of estrogen‑deficient conditions of the lower genital tract. The product delivers a low‑dose estrogen effect while supporting normal vaginal flora, offering a dual mechanism for managing vulvovaginal atrophy in post‑menopausal women.

Gynoflor is indicated for several estrogen‑related gynecological conditions, primarily in women experiencing menopause or hypo‑estrogenism.

- Relief of vulvovaginal atrophy symptoms such as dryness, itching, and burning. - Reduction of dyspareunia (painful intercourse) associated with low estrogen levels. - Restoration of normal vaginal pH and flora through the probiotic component. - Adjunctive therapy for mild to moderate menopausal symptoms affecting the genital tract. - Prevention of recurrent urinary tract infections linked to altered vaginal microbiota.

The safety profile of Gynoflor reflects the local action of estriol and the probiotic, with most adverse events being mild and transient.

Common: - Vaginal irritation or mild burning sensation. - Spotting or light vaginal bleeding. - Increased vaginal discharge that is non‑purulent. - Transient abdominal cramping or bloating.

Serious: - Allergic reaction such as rash, itching, or swelling of the face and throat. - Severe vaginal bleeding or hemorrhage. - Thromboembolic events (rare, associated with systemic estrogen exposure).

Before prescribing Gynoflor, clinicians should evaluate patient history and consider specific contraindications and safety considerations.

- Known hypersensitivity to estriol, Lactobacillus species, or any tablet excipients. - Active or past history of estrogen‑dependent neoplasia (e.g., breast or endometrial cancer). - Undiagnosed abnormal uterine bleeding. - History of thromboembolic disorders, stroke, or myocardial infarction. - Pregnant or breastfeeding women, as safety has not been established. - Liver disease that may affect estrogen metabolism.

Because Gynoflor delivers estrogen locally, systemic drug interactions are limited but still warrant attention.

Avoid: - Systemic estrogen therapy (e.g., oral contraceptives, hormone replacement) that could increase overall estrogen exposure. - Antifungal or antibacterial vaginal products used concurrently, which may alter probiotic viability.

Use with caution: - Medications that increase the risk of thrombosis (e.g., tamoxifen, selective estrogen receptor modulators). - Systemic corticosteroids or immunosuppressants that could affect infection risk. - Herbal supplements with estrogenic activity (e.g., black cohosh, phytoestrogens).